LONDON, Nov 19 (Reuters) - Oxford University will start an initial analysis of data from its late-stage trial of the experimental COVID-19 vaccine it is developing with AstraZeneca after 53 infections among its volunteers, the study’s chief investigator said on Thursday.
The Oxford Vaccine Group’s director Andrew Pollard said there were “lots of cases” of infections in its Phase III trial in Britain, Brazil and South Africa.
The first two sets of interim data from vaccine trials from Pfizer and BioNTech last week and Moderna on Monday were released after more than 90 infections among volunteers. (Reporting by Alistair Smout and Kate Kelland; Writing by Josephine Mason; Editing by Alex Richardson)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.